Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

GW van Imhoff; A McMillan; MJ Matasar; J Radford; KM Ardeshna; K Kuliczkowski; W Kim; XN Hong; JS Goerloev; A Davies; MDC Barrigon; M Ogura; S Leppa; M Fennessy; QM Liao; Ronnie van der Holt; S Lisby; A Hagenbeek

doi:10.1200/jco.2016.69.0198

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

GW van Imhoff, A McMillan, MJ Matasar, J Radford, KM Ardeshna, K Kuliczkowski, W Kim, XN Hong, JS Goerloev, A Davies, MDC Barrigon, M Ogura, S Leppa, M Fennessy, QM Liao, Ronnie van der Holt, S Lisby, A Hagenbeek

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

116 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	544-+
Journal	Journal of Clinical Oncology
Volume	35
Issue number	5
DOIs	https://doi.org/10.1200/jco.2016.69.0198
Publication status	Published - 2017

Access to Document

10.1200/jco.2016.69.0198

http://hdl.handle.net/1765/98019

Cite this

van Imhoff, GW., McMillan, A., Matasar, MJ., Radford, J., Ardeshna, KM., Kuliczkowski, K., Kim, W., Hong, XN., Goerloev, JS., Davies, A., Barrigon, MDC., Ogura, M., Leppa, S., Fennessy, M., Liao, QM., van der Holt, R., Lisby, S., & Hagenbeek, A. (2017). Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. Journal of Clinical Oncology, 35(5), 544-+. https://doi.org/10.1200/jco.2016.69.0198

@article{604044b94b63488a8f48cb0010aa2db2,

title = "Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study",

author = "{van Imhoff}, GW and A McMillan and MJ Matasar and J Radford and KM Ardeshna and K Kuliczkowski and W Kim and XN Hong and JS Goerloev and A Davies and MDC Barrigon and M Ogura and S Leppa and M Fennessy and QM Liao and {van der Holt}, Ronnie and S Lisby and A Hagenbeek",

year = "2017",

doi = "10.1200/jco.2016.69.0198",

language = "Undefined/Unknown",

volume = "35",

pages = "544--+",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "5",

}

van Imhoff, GW, McMillan, A, Matasar, MJ, Radford, J, Ardeshna, KM, Kuliczkowski, K, Kim, W, Hong, XN, Goerloev, JS, Davies, A, Barrigon, MDC, Ogura, M, Leppa, S, Fennessy, M, Liao, QM, van der Holt, R, Lisby, S & Hagenbeek, A 2017, 'Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study', Journal of Clinical Oncology, vol. 35, no. 5, pp. 544-+. https://doi.org/10.1200/jco.2016.69.0198

TY - JOUR

T1 - Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

AU - van Imhoff, GW

AU - McMillan, A

AU - Matasar, MJ

AU - Radford, J

AU - Ardeshna, KM

AU - Kuliczkowski, K

AU - Kim, W

AU - Hong, XN

AU - Goerloev, JS

AU - Davies, A

AU - Barrigon, MDC

AU - Ogura, M

AU - Leppa, S

AU - Fennessy, M

AU - Liao, QM

AU - van der Holt, Ronnie

AU - Lisby, S

AU - Hagenbeek, A

PY - 2017

Y1 - 2017

U2 - 10.1200/jco.2016.69.0198

DO - 10.1200/jco.2016.69.0198

M3 - Article

SN - 0732-183X

VL - 35

SP - 544-+

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5

ER -